Zobrazeno 1 - 2
of 2
pro vyhledávání: '"L. B. Egoryan"'
Autor:
O. Yu. Vinogradova, M. M. Pankraskina, A. L. Neverova, D. I. Shikhbabaeva, M. A. Murzabekova, M. V. Chernikov, A. V. Popova, V. P. Kosenkova, L. B. Egoryan, V. V. Ptushkin
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 16-33 (2024)
Background. Currently, targeted therapy is the most promising for the treatment of myelofibrosis (MF). Today, the results of many years of experience with the use of ruxolitinib, including outside randomized trials and the identification of predictor
Externí odkaz:
https://doaj.org/article/32b92dd0c58149d28216d7e1ea000c8a
Autor:
O. Yu. Vinogradova, D. I. Shikhbabaeva, Yu. N. Kobzev, A. L. Neverova, M. M. Pankraskina, S. G. Malakho, M. V. Chernikov, M. A. Murzabekova, A. G. Popova, L. B. Egoryan, A. V. Krechetova, V. V. Ptushkin
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 115-134 (2023)
Background. Targeted therapy is the most promising in the treatment of myelofibrosis, but it is necessary to search for the reasons limiting its effectiveness. There are known factors negatively affecting the development of myelofibrosis, but data on
Externí odkaz:
https://doaj.org/article/acfa0f73165445de81595ace088e5592